Tyrosine kinase inhibitors (TKI) have improved outcomes in EGFR-mutant non-small cell lung cancer (NSCLC), but unmet needs remain. Even with third-generation options, the majority of patients will eventually develop disease progression due to acquired resistance. Now, a growing understanding of the mechanisms of acquired resistance is paving the way for personalised management that may improve outcomes.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


